Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients
Open Access
- 1 February 2007
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (2) , 257-259
- https://doi.org/10.1136/ard.2006.054346
Abstract
Introduction: Systemic sclerosis (SSc) is characterised by disturbed vessel morphology and an overproduction of vascular endothelial growth factor (VEGF). The VEGF gene located on chromosome 6p21.3 has several polymorphisms. Objective: To test the hypothesis that disturbed angiogenesis may be related to the genetic background of the VEGF gene. Materials and methods: EUSTAR centres included European Caucasian patients with SSc and matched controls with osteoarthritis. The VEGF gene was genotyped by polymerase chain reaction, followed by restriction enzyme analysis. The 634 C/T and 936 C/G mutations and an 18-base pair insertion/deletion at −2549 of the VEGF promoter region were tested. Results: 416 patients with SSc and 249 controls were included in the study population. Of the patients with SSc, 42% had a diffuse cutaneous subtype, 16% had increased pulmonary arterial pressure and 61% had decreased carbon monoxide diffusion capacity. The genotype frequencies in the patients with SSc and in controls were in Hardy–Weinberg equilibrium. The allele and genotype frequencies of the polymorphisms did not differ between patients with SSc and controls. No association was found between these polymorphisms and disease phenotypes. Conclusion: This study shows that there is no association between the three selected functional VEGF polymorphisms and SSc.Keywords
This publication has 16 references indexed in Scilit:
- The effect of genetic diversity on angiogenesisExperimental Cell Research, 2006
- Vascular involvement in systemic sclerosis (SSc).2004
- Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic SclerosisCirculation Research, 2004
- Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1Arthritis Research & Therapy, 2004
- Raynaud's phenomenon and the role of capillaroscopyArthritis & Rheumatism, 2003
- Assessment of lung involvement.2003
- Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitusJournal of Diabetes and its Complications, 2002
- A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma LevelsJournal of Vascular Research, 2000
- Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor geneHuman Immunology, 1999
- Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.1988